A cross-skin management system comprising methamphetamine or its salts as active ingredients. Some methods have also been adopted to provide effective methamphetamine treatment for patients with pathological conditions. This pathological condition includes neurological disorders.For example, attention deficit disorder (ADD) and/or hyperactivity disorder (ADHD) are attention deficit disorders. In addition, it also includes cross-skin management systems and methods of manufacturing and using cross-skin management systems. Proposition 1: A matrix layer consisting of: (1) silicone binder； (2) a matrix layer consisting of (a) methylbenzoate or its pharmaceutically acceptable salts； and (b) a rubber-based polymer. It is an improver for hydrogenated synthetic adhesives.In this case, within 2-18 hours after the start of treatment, the flow rate of the skin management system varies from about 6 mg/km2/hour to 100 mg/km2/hour. Claim 2: The cross-skin management system described in Claim 1, in which the rubber polymer is a block copolymer rubber of styrene-butadiene. Proposition 3: A cross-skin management system based on any of the above requirements basically includes a support layer, a silicone adhesive, a matrix layer containing the drug and an anti-adhesive.Un sistema de administración transdérmica que comprende metilfenidato o su sal como ingrediente activo. También métodos para administrar una cantidad terapéuticamente eficaz de metilfenidato a un sujeto para el tratamiento de una condición patológica. Esta condición patológica incluye una afección neurológica, tal como el trastorno por déficit de atención (ADD) y/o el trastorno por déficit de atención con hiperactividad (ADHD). También kits que incluyen el sistema de administración transdérmica y métodos para fabricar y usar el sistema de administración transdérmica. Reivindicación 1: Un sistema de administración transdérmica que comprende: (i) una capa adhesiva de silicona； y (ii) una capa con matriz que contiene el fá
